We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Read MoreHide Full Article
Sensus Healthcare, Inc. (SRTS - Free Report) closed the latest trading day at $4.78, indicating a +0.84% change from the previous session's end. This change lagged the S&P 500's 1.08% gain on the day. At the same time, the Dow added 0.92%, and the tech-heavy Nasdaq gained 1.41%.
The company's shares have seen a decrease of 18.84% over the last month, not keeping up with the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26%.
Investors will be eagerly watching for the performance of Sensus Healthcare, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.08, showcasing a 42.86% downward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $7.93 million, down 25.61% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.33 per share and revenue of $41.82 million, indicating changes of -19.51% and +0.03%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Sensus Healthcare, Inc. is currently a Zacks Rank #4 (Sell).
With respect to valuation, Sensus Healthcare, Inc. is currently being traded at a Forward P/E ratio of 14.59. This indicates a discount in contrast to its industry's Forward P/E of 28.19.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 129, putting it in the bottom 49% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Sensus Healthcare, Inc. (SRTS) Gained But Lagged the Market Today
Sensus Healthcare, Inc. (SRTS - Free Report) closed the latest trading day at $4.78, indicating a +0.84% change from the previous session's end. This change lagged the S&P 500's 1.08% gain on the day. At the same time, the Dow added 0.92%, and the tech-heavy Nasdaq gained 1.41%.
The company's shares have seen a decrease of 18.84% over the last month, not keeping up with the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26%.
Investors will be eagerly watching for the performance of Sensus Healthcare, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.08, showcasing a 42.86% downward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $7.93 million, down 25.61% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.33 per share and revenue of $41.82 million, indicating changes of -19.51% and +0.03%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Sensus Healthcare, Inc. is currently a Zacks Rank #4 (Sell).
With respect to valuation, Sensus Healthcare, Inc. is currently being traded at a Forward P/E ratio of 14.59. This indicates a discount in contrast to its industry's Forward P/E of 28.19.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 129, putting it in the bottom 49% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.